Abbott Laboratories stock (US0028241000): investors eye upcoming Q4 2025 earnings call and biosimilar expansion

Abbott Laboratories has scheduled its fourth-quarter 2025 earnings call for January 22, 2026, while investors also focus on the company’s biosimilar strategy and recent institutional positioning in the stock.

Abbott Laboratories is drawing investor attention ahead of its next earnings event and on the back of strategic product moves and shifting institutional positions. The healthcare group has scheduled the release of its fourth-quarter 2025 results and a related webcast for late January 2026, while commentary from research providers highlights the role of biosimilars in driving emerging markets growth. At the same time, recent regulatory filings show that some institutional investors have adjusted their holdings in the New York–listed stock, giving the market fresh data points on sentiment toward Abbott’s diversified healthcare portfolio, which includes significant exposure to the US medical devices and diagnostics markets, according to StockTitan/PR Newswire as of 01/05/2026 and MarketBeat as of 05/20/2026.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Abbott Laboratories
• Sector/industry: Healthcare, medical devices, diagnostics and nutrition
• Headquarters/country: Abbott Park, Illinois, United States
• Core markets: United States, Europe, Latin America, Asia-Pacific and other emerging markets
• Key revenue drivers: Medical devices, diagnostics, established pharmaceuticals and nutrition products
• Home exchange/listing venue: New York Stock Exchange (ticker: ABT)
• Trading currency: US dollar (USD)

Abbott Laboratories: core business model

Abbott Laboratories operates as a diversified healthcare company with four major reportable segments: medical devices, diagnostics, established pharmaceuticals and nutrition. Its medical devices portfolio spans cardiovascular, diabetes care, neuromodulation and structural heart solutions, placing the company among the larger device suppliers to US hospitals and clinics. The diagnostics division provides laboratory systems, rapid tests and molecular platforms used by health systems, reference labs and other providers worldwide. Complementing these units, Abbott’s established pharmaceuticals business focuses largely on branded generics in emerging markets, while the nutrition segment offers pediatric and adult nutrition products, including formulas and specialized medical nutrition.

The company’s business model hinges on a combination of recurring revenue from consumables and long product life cycles for complex devices and systems. In diagnostics, for example, installed instruments typically generate multi-year reagent and service revenue streams as healthcare providers continue to run tests. In medical devices, Abbott aims to introduce differentiated technologies, such as minimally invasive cardiovascular therapies or continuous glucose monitoring systems, that can capture share in growing clinical markets. This mix gives Abbott exposure to both volume-driven emerging markets and higher-value procedures in developed healthcare systems, particularly in the United States. The company’s scale, extensive distribution network and R&D capabilities are central to sustaining this model.

From a geographic perspective, the United States remains a core market for Abbott’s medical devices and diagnostics operations, reflecting the scale of the US healthcare system and its reimbursement frameworks. However, the established pharmaceuticals segment is more heavily weighted toward emerging economies, where Abbott markets branded generics and specialty drugs tailored to local needs and regulatory environments. This diversification can help smooth revenue across economic cycles and policy changes, though it also introduces currency and regulatory risks. Across its segments, Abbott typically pursues incremental innovation and line extensions, rather than relying solely on one-off blockbuster products, which can offer a more balanced growth profile over time.

Main revenue and product drivers for Abbott Laboratories

Medical devices represent a significant revenue and earnings driver for Abbott, with key franchises in cardiovascular technologies and diabetes care. Products such as stents, transcatheter valves and structural heart devices are used in interventional cardiology procedures, an area that continues to grow as populations age and cardiovascular disease remains a leading cause of morbidity. The company’s diabetes care portfolio, which includes continuous glucose monitoring systems, taps into increasing global demand for better long-term management of diabetes. These device platforms can generate recurring revenue through sensors and associated supplies, alongside potential data and software offerings that help patients and providers track metrics more closely over time.

Diagnostics is another central pillar in Abbott’s revenue mix, covering core laboratory systems, point-of-care tests and rapid diagnostics. Hospitals, laboratories and clinics rely on these systems for routine blood tests, infectious disease screening and other analyses. During recent years, global demand for diagnostics has remained elevated as healthcare systems emphasize early detection and monitoring for a range of conditions. Abbott’s installed base of instruments can support recurring reagent sales, and new test menu additions can deepen utilization. At the same time, the company’s nutrition segment sells pediatric and adult products through retail channels, hospitals and specialized medical programs, contributing a consumer-facing element that differs from the capital equipment model of devices and diagnostics.

Analyst commentary has also highlighted the role of Abbott’s established pharmaceuticals division, particularly its push into biosimilars, in supporting growth in emerging markets. A recent analysis noted that Abbott is expanding its biosimilar portfolio to strengthen the performance of its established products division, with the company trading at a forward five-year price/earnings multiple of about 15.6 times, below its longer-term median and roughly in line with an industry average of about 15.6 times, according to Zacks via TradingView as of 04/18/2026. While valuation metrics can change with share price moves and earnings updates, the focus on biosimilars underscores Abbott’s strategy to capture demand for cost-effective therapies as healthcare systems seek to manage spending.

Upcoming Q4 2025 earnings call and market expectations

Abbott has announced that it will release its financial results for the fourth quarter of 2025 on Thursday, January 22, 2026, before the US market opens. On the same day, management is scheduled to host a conference call and webcast at 8:00 a.m. Central Time, or 9:00 a.m. Eastern Time, accessible through the company’s investor relations website. An archived version of the webcast is expected to be made available for replay later that day, allowing investors and analysts who cannot attend live to review management’s comments on recent business trends, segment performance and guidance for the coming year, according to StockTitan/PR Newswire as of 01/05/2026.

The announcement of the Q4 2025 earnings schedule has already attracted attention in the market, as this reporting period will offer updated insight into post-pandemic demand patterns and the trajectory of Abbott’s core franchises. Investors often focus on key metrics such as segment revenue growth, operating margins and cash flow, as well as any guidance Abbott might provide for fiscal 2026. Commentary on the performance of its diabetes care and structural heart businesses, as well as trends in diagnostics volumes, typically features prominently in these calls. While the company has not yet reported the actual Q4 2025 results, the timing of the call gives analysts a clear date to refine their models and expectations based on any preliminary indications or broader sector signals.

Market reactions to scheduling announcements can sometimes be modest, but in this case the shares recorded a mild positive move on the day the earnings call was announced, reflecting the steady interest in upcoming catalysts. On the day the news of the Q4 2025 conference call was published, Abbott’s stock gained around 1.05%, indicating a constructive, if measured, response from investors, according to data cited by StockTitan/PR Newswire as of 01/05/2026. For US-focused portfolios, earnings dates like this can serve as key checkpoints for reassessing exposure to large-cap healthcare names, particularly given Abbott’s role as a component of major indices and its significance in the medical device and diagnostics landscape.

Institutional positioning and analyst backdrop

Recent regulatory filings provide a snapshot of how institutional investors have been adjusting their exposure to Abbott Laboratories. One filing showed that Csenge Advisory Group reduced its stake in Abbott by about 46.7% during the fourth quarter, according to its most recent Form 13F submitted to US regulators, indicating that this particular advisory group chose to scale back its allocation to the stock during that period, as reported by MarketBeat as of 05/20/2026. Such adjustments can reflect firm-specific portfolio decisions, client flows or relative value views and do not necessarily signal a broad consensus shift on the company.

In contrast, another institutional update indicated that Harvest Portfolios Group increased its position in Abbott in a recent quarter, highlighting that not all institutional investors are moving in the same direction at the same time. That filing noted that Harvest Portfolios Group grew its holdings in the stock, while also citing commentary from a major investment bank. Specifically, an analyst report from Jefferies Financial Group trimmed its price target on Abbott shares from $145.00 to $135.00 while maintaining a "buy" rating, according to MarketBeat as of 05/20/2026. Across the broader analyst community, Abbott is often described with moderately positive language, with some aggregators assigning it an average rating in the "moderate buy" range based on multiple brokerage views.

Retail investors in the United States may look at these data points for context but often combine them with their own assessment of the company’s fundamentals and sector outlook. Institutional buying or selling, as disclosed in Form 13F filings, is backward-looking by nature, reflecting holdings at the end of a quarter. Analyst price targets and ratings, meanwhile, can change as new information emerges, including earnings reports, regulatory developments or competitor news. As Abbott approaches its Q4 2025 reporting date, analysts may update their models for factors such as potential biosimilar uptake, device procedure volumes and any signs of margin expansion or compression in key segments.

Why Abbott Laboratories matters for US investors

For US investors, Abbott Laboratories represents a diversified exposure to healthcare products and technologies that are deeply embedded in domestic and global health systems. The company’s New York Stock Exchange listing and inclusion in major indices make it a widely followed name among institutional and retail investors alike. US-based hospitals and clinics use Abbott’s medical devices and diagnostic systems in everyday clinical practice, so trends in procedure volumes, insurance coverage and public health policy can have a tangible impact on the company’s performance. In addition, US consumers purchase Abbott’s nutrition products through retail channels, linking the company’s results in part to consumer spending patterns and demographic shifts.

Another aspect of interest for US investors is Abbott’s role in areas such as cardiovascular care and diabetes management, which are high-prevalence conditions in the United States. Technologies that enable earlier detection, less invasive treatments or improved long-term monitoring can be strategically important for healthcare providers and insurers seeking to manage outcomes and costs. Abbott’s research and development efforts in these fields, coupled with regulatory approvals from the US Food and Drug Administration when applicable, can create new revenue streams over time. For investors, this means that product pipelines, clinical trial milestones and FDA decisions are key elements to watch alongside quarterly revenue and earnings metrics.

Because Abbott generates a substantial portion of its revenue outside the United States as well, the stock can also offer US investors a measure of international diversification within the healthcare sector. Exposure to emerging markets through the established pharmaceuticals and nutrition segments can provide growth opportunities that differ from those available purely in domestic markets. However, this also introduces additional variables, such as foreign exchange movements and regional regulatory or economic shifts. Balancing these factors is an ongoing consideration for investors monitoring the stock, particularly when global conditions are volatile or when policy changes affect cross-border healthcare spending and market access.

Conclusion

Abbott Laboratories enters the next reporting phase with a scheduled Q4 2025 earnings call in January 2026, a diversified mix of medical devices, diagnostics, nutrition and established pharmaceuticals, and active discussion around its biosimilar strategy in emerging markets. Institutional filings reveal that some investors have reduced their stakes while others have added to positions, underscoring differing views on valuation and risk-reward. Analyst commentary, including a recent target cut paired with a continued buy rating from a major bank, reflects expectations for ongoing growth but also acknowledges sector-wide and company-specific uncertainties. For US investors, Abbott’s role in critical areas such as cardiovascular care, diabetes management and diagnostics, combined with its global footprint, makes it a significant healthcare holding to watch as upcoming earnings and product developments unfold.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.